Does ceftazidime or latamoxef affect the phagocytic capabilities of human granulocytes?
In comparative studies made in patients with pneumonia we have treated 14 cases with Latamoxef and 16 cases with Ceftazidime. We have focused attention on the side effects of these drugs and on the phagocytic capacity of granulocytes. In our patients we have noted a decrease of bactericidal activity of plasma and granulocytes and an elevated NBT reduction capability of resting granulocytes. The other tested function of the granulocytes exhibited only small variations. The applied therapy caused the bactericidal activity to be increased in granulocytes and plasma. Both drugs had no harmful effect on the phagocytic activities of granulocytes.
D001424:Bacterial Infections / Q000188:drug therapy; D001770:Blood Bactericidal Activity / Q000187:drug effects; D002442:Ceftazidime / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005260:Female; D006098:Granulocytes / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009070:Moxalactam / Q000009:adverse effects*; D009580:Nitroblue Tetrazolium; D010587:Phagocytosis / Q000187:drug effects*; D011897:Random Allocation
D009580:Nitroblue Tetrazolium; D002442:Ceftazidime; D009070:Moxalactam